Abstract
Introduction

Under normal conditions, vascular capillary endothelial cells form tight junctions with each other ensuring that there is no net movement of plasma into peripheral organ tissues. Resting endothelial cells express adhesion molecules at low level and there is very limited presentation of chemoattractant cytokines (chemokines) on the luminal extracellular matrix. Few leucocytes are recruited into sub-endothelial tissues and normal tissue function is maintained by homeostatic processes.
Pathogens or other stimuli can trigger an inflammatory response in the periphery by induction of signalling by Toll-like receptors (TLRs) expressed on sentinel cells. Dendritic cells (DC) are perhaps the most important cells of this type: tissue resident DC, such as Langerhans cells, express a wide range of TLRs and are therefore able to respond to many different pro-inflammatory cues. These include pathogen-derived nucleic acids and lipids, and also endogeneous components -for example histones.
• (Fig. 1) .
Production of inflammatory mediators, including tumour necrosis factor (TNF)-␣, results in a reduction in endothelial barrier integrity and an increase in the amount of fluid (containing a number of non-cellular components which contribute to inflammation, including complement proteins) exuded into the local tissue. Adhesion molecules, including selectins and Ig-domain containing-molecules such as ICAM-1 and VCAM-1 become highly expressed on the surface of endothelial cells. Chemokines released within the tissue are also presented on the luminal surface of the endothelium. The result is that the fluid exudate is accompanied by an influx of captured leucocytes, which under healthy conditions would help resolve the inflammation
The endogeneous compound sphingosine 1-phosphate (S1P) plays a central role in the regulation of the vascular and immune systems in the resting state and inflammation. There is an extensive literature on the involvement of S1P in the processes of angiogenesis and regulation of arterial vascular tone [1, 2] . The focus of this review lies at the interface of the vascular and immune systems: in this regard, two aspects of S1P biology are of key concern. First, S1P is effectively compartmentalized in different regions of the lymphatic and circulatory systems. Second, whilst the receptors for S1P are widely expressed, the functioning of particular receptor types is dependent on the immune state. This review explores these concepts in further detail.
Biochemistry of sphingosine 1-phosphate
S1P is a bioactive lipid and member of the lysophospholipid family. It is 379 Da in size and consists of a polar head group and a long saturated aliphatic tail (Fig. 2).
Generation S1P is generated inside cells through the action of sphingosine kinases 1 and 2 (SK1 and 2) on the primary hydroxyl group of sphingosine (which comprises a hydrophobic backbone and hydrophilic head group). Sphingosine is itself generated from the metabolism of sphingolipids, structural components of all eukaryotic cell membranes; this synthetic pathway is widespread among mammalian cells [3] [4] [5] . The primary mechanism by which S1P is produced involves the degradation of sphingomyelin (a membrane component enriched in lipid rafts) to ceramide, conversion to sphingosine and finally phosphorylation to produce S1P [6] . An important aspect of S1P biochemistry is the existence of the sphingolipid 'rheostat' inside cells. Sphingosine (and ceramide, with which it can be interconverted) promotes apoptosis, whereas S1P suppresses apoptosis and causes cell proliferation. Hence, the balance of these lipid metabolites determines cell survival, and the relative activity of the S1P synthetic and degradative enzymes is an important regulator of cell fate [5, 7] [3, 8, 9] . Activation of SK1 is essential for the pro-inflammatory effects on endothelium of cytokines such as TNF-␣ [2, 10] . Activation occurs through phosphorylation and translocation of the enzyme to the plasma membrane (into the vicinity of its substrate, where it causes localized production of S1P [11] [12] . They have six transmembrane domains and efficiently form oligomers in cell membranes [13] . LPP activity on the extracellular side of the plasma membrane (ecto-LPP) would be expected to reduce S1P receptor signalling activity through depletion of the agonist; intracellular LPP could influence second messenger signalling by S1P. S1P can also be depleted through irreversible degradation by its specific lyase to phosphoethanolamine and hexadecanal. S1P lyase is predominantly localized within the ER, with the active site facing the cytosol and appears to have a purely intracellular function [14, 15] . In this context, we are concerned with the critical role played by the enzyme in control of the steady state levels of S1P in different compartments of the immune system. S1P lyase expression is absent in platelets [16] and erythrocytes [17] ; expression is higher in tissue, particularly, for example in the thymus [18] . This generates a vascular S1P gradient [5, 18, 19] . Inhibition of S1P lyase by 2-acetyl-4-tetrahydroxybutylimidazole caused a dramatic effect on the distribution of lymphocytes in mice through disruption of this gradient [18] . [20] , in mast cells ABCC1 [21] and rat erythrocytes appear to utilize a novel ATPdependent transporter [22] . It has been reported that S1P export by ABCC1 and autologous signalling via S1PR3 is necessary for the cytoprotective effect of dexamethasone on human fibroblasts [23] . Others have shown that the CFTR can regulate S1P uptake in a murine epithelial cell line [24] . Localized export of S1P and autocrine signalling is necessary for cell chemotaxis towards certain ligands -so-called inside-out signalling. Chemotaxis to platelet-derived growth factor (PDGF) showed dependence on SK and S1PR1 expression. These data are consistent with a mechanism in which PDGF signalling causes a membrane-proximal local increase in S1P production. The S1P is then exported and binds its specific GPCR to induce directional migration [7, 25] .
S1P receptor biology
Extracellular S1P signals mainly through a family of five receptors denoted S1PR1-5. These have a high degree of sequence similarity and all belong to the heterotrimeric GPCR superfamily [26] . S1PR1 is expressed widely on immune cells, whereas the other receptor types have more limited expression, for example S1PR4 expression by T lymphocytes [27] and S1PR5 expression by NK cells [28] . Receptor expression can be either constitutive or modulated, depending on the cell type. The affinity of S1P for these receptors (Kd) is mostly in the sub-nanomolar range [29, 30] . FTY720-P, the phosphorylated form of the drug FTY720 and a structural analogue of S1P, is a potent agonist of S1PR1, 3, 4 and 5 [31] . SEW2871 by contrast does not structurally resemble S1P and is a selective agonist of S1PR1 [32] .
The receptors couple to a variety of downstream signalling pathways (Fig. 3 [34] , whereas at much higher concentrations of ligand S1PR1 and other S1P receptor subtypes can be internalized (and also degraded) [35] . [36, 37] . Interestingly, S1P is required for the transduction of signals by certain other GPCR (inside-out signalling) [3] . S1P can also act intracellularly and independently of S1PR1-5 to enhance cell proliferation and suppress apoptosis. This has been shown in the MCF-7 cell line, where depletion of SK2 attenuated the ability of phorbol myristate acetate to cause acetylation of histone H3 at the p21 and c-fos promoters. SK2 can physically associate with, and S1P can suppress the activity of, histone deacetylases 1 and 2 in the nucleus [38] . S1PR1 is the most highly expressed S1P receptor on lymphocytes and seems to be exclusively responsible for mediating the effects of S1P on cell trafficking. Similarly, S1PRs 1 and 3 are abundantly expressed by endothelial cells and seem largely responsible for transduction of the effects of their ligand on that cell type. These receptors are described in further detail below. [40] [41] [42] . S1PR1 couples to the G protein G␣i alone, as shown by the complete inhibition of S1PR1-mediated responses by pertussis toxin [43] . [3, 33] .
S1PR1-5 are responsible for mediating many of the effects of S1P on cell biology including proliferation, cell migration, invasion, angiogenesis and vascular maturation, actin cytoskeleton rearrangement and adherens junction assembly
S1PR1
S1PR1 is expressed by a wide variety of tissues in mice and human beings. S1PR1-KO (knockout) mice die between E12.5 and E14.5 due to severe haemorrhage resulting from a defect in vascular stabilization [39]. Conditional gene deletion and experiments using selective receptor agonists show that the receptor has additional roles in angiogenesis, immune cell trafficking, regulation of vascular tone and endothelial barrier function
Through the activation of G␣i, receptor signalling results in an increase in mitogen-activated protein kinase activity, decrease in adenylate cyclase activity, increase in phospholipase C (PLC) activity, increase in Rac activation and increase in phosphatidyl inositol 3-kinase activity. Binding of S1P to S1PR1 transactivates receptor tyrosine kinases including the vascular endothelial growth factor (VEGF) and PDGF receptors. This occurs through intracellular receptor crosstalk, direct phosphorylation of receptor tyrosine kinases by protein tyrosine kinases, induced production or secretion of other receptor ligands and the formation of signalplexes
Plasma-membrane S1PR1 is internalized into endosomal compartments on receptor activation. The G protein receptor kinase GRK2 is activated on receptor signalling and phosphorylates the C-terminal tail of S1PR1 to initiate endocytosis [5] . Recently [45] . S1PR1 can undergo polyubiquitinylation upon internalization [46] . The degree of polyubiquitinylation is dependent on the type and concentration of agonist. The poorly ubiquitinylated receptor recycles from the late endosomal compartment back to the plasma membrane, the highly ubiquitinylated receptor is degraded in lysosomes [29] . Interestingly, activation of T cells through the T-cell receptor results in translocation of plasma membrane resident S1PR1 to the nuclear envelope, where the receptor affects changes in gene transcription (rather than, e.g. promoting cell migration) [47] . S1PR1 plays a central role in the S1P-mediated control of lymphocyte trafficking. It alone is sufficient to control lymphocyte recirculation, as shown by S1PR3 KO mice and selective receptor agonists [32] . Natural and functionally similar S1PR1 agonists are sufficient for the maintenance and enhancement of endothelial integrity [2, 48, 49] .
S1PR3
Like S1PR1, S1PR3 is expressed widely in mice and human beings, particularly in the heart, lungs and kidneys. Deletion of the gene that codes for S1PR3 does not, however, result in any obvious abnormality [50] . The receptor couples to the G␣i, G␣12/13, G␣s and G␣q proteins, although the coupling to G␣q appears to predominate [33] [51] . Evidence suggests that S1P and its analogues can influence heart rate through S1PR3. Non-selective S1P receptor agonists in S1PR3 KO mice and S1PR1 selective agonists in wild-type mice do not induce bradycardia, implicating S1PR3 and not S1PR1 in bradycardia [32] in this species.
The vascular gradient of sphingosine 1-phosphate Compartmentalization
The levels of S1P in the various compartments of the mammalian immune system are tightly controlled. S1P is present at single unit micromolar concentration in human serum, although reported values vary widely [17, 52] , where it is mostly bound to lipoproteins, particularly HDL, and albumin [53] (Fig. 1A) . Erythrocytes express SKs and lack both S1P lyase and LPPs and are the primary source of S1P in blood [54] , and appear to be able to buffer its concentration there [17] . There also exists evidence for the transcellular transport of S1P from erythrocytes to other cell types including endothelial cells, and thus into tissues [55] . It has also been reported that vascular endothelium is a significant contributor to S1P in blood, and indeed endothelial cells respond to shear flow by modulating the level of S1P metabolic enzymes [56] . They are able to internalize and store S1P. HDL and serum albumin are the major triggers for erythrocyte S1P release into the blood [55] . S1P is present in lymph at around one quarter the level in blood. Experiments with tissue-specific conditional SK1 and constitutive SK2 KO mice have shown that lymphatic endothelial cells are the source of S1P in lymph, and that expression of the enzyme there is required for normal lymphocyte egress from lymph nodes and Peyer's patches [57] . S1P is at a very low concentration in primary and secondary lymphoid tissue: the levels of S1P in thymus, lymph nodes and spleen are 20, 40 and 150 ng per g of tissue, respectively. A high level of S1P lyase activity in these tissues underlies this low concentration, as shown by the dramatic increase in tissue abundance of S1P on enzyme inhibition [18] . [58] .
T-cell trafficking
S1P plays a pivotal role in the immune system of mammals through its role in the control of lymphocyte egress from the thymus and secondary lymphoid tissue. This regulation is achieved through changes in the surface expression of S1PR1 on lymphocytes resulting from homologous desensitization of the receptor and by transduction of other cell signals
T cells present in blood are exposed to a high concentration of S1P. This results in marked internalization of S1PR1 to endosomes and loss of sensitivity to extracellular S1P (Fig. 1A) . This contrasts with the very low concentration found within lymphoid tissue in non-inflammatory conditions. So, S1PR1 that is sequestered in endosomes recycles onto the T-cell surface within a few hours of T-cell entry into such tissue [59] . [60, 61] . [40] . [63] . (Fig. 1A) 
Resting T cells patrol the paracortex of the lymph node and move towards exit structures under the influence of chemokines, most notably CCL19 which is produced by stromal cells there and binds surface CCR7. It has been proposed that T cells receive opposing retention and egress signals (via CCR7 and S1PR1, respectively) when adjacent to the cortical sinusoids. The signalling through S1PR1, which is strongest in the immediate vicinity of exit structures, overcomes the CCR7-mediated retention signal and cause T-cell egress
The situation is different under inflammatory conditions where the egress process is shut down locally and transiently in the course of an immune response. Activation of a T cell through the T-cell receptor (with co-stimulation), or simply through innate immune cytokines, causes up-regulation of CD69, which physically associates with S1PR1 and renders cells insensitive to signalling through this receptor [62]. The cell consequently does not receive exit signals and remains in the lymphoid tissue where it can proliferate and differentiate into other cell subtypes. The expression of CD69 is reduced following T-cell differentiation to an effector phenotype, allowing cells to exit
There is also evidence for a role of lymphocyte intrinsic S1P signalling in control of T-cell movement from peripheral tissue into afferent lymphatics during inflammation (when the extracellular concentration of S1P concentration can increase). It has been shown that agonism of S1PR1 on T cells prevented movement of T cells across lymphatic endothelium. This was found to be dependent on the interaction of LFA-1 and VLA-4 on the T cells with their ligands ICAM-1 and VCAM-1 on the endothelium
Role of S1P on vascular endothelium
Maintenance of endothelial barrier integrity in the resting state
Maintenance of vascular barrier integrity under normal conditions is necessary for proper organ function. Paracellular permeability, the passive movement of solutes with molecular radii less than 3 nm, is the main determinant of endothelial barrier permeability [64]. Barrier permeability is maintained by a complex balance of tethering forces at cell-cell and cell-matrix level as well as intracellular contractile forces mediated by actin and myosin. Endothelial cells are connected to each other by three junctional complexes: adherens junctions, tight junctions and gap junctions. S1P enhances the integrity of vascular barrier through agonism of the receptor S1PR1
Disruption of barrier integrity during inflammation
During inflammation, thrombin antagonizes the effects of S1PR1 signalling to increase paracellular permeability. This occurs through activation of the Rho signalling pathway, causing cell contraction and disruption of the endothelial barrier [70] (Fig. 1C) [72] . TGF-␤ signalling has been shown to be necessary in stabilization of the peripheral microvasculature, and TGF-␤ is a central player in the chronic inflammatory process [73, 74] . There is therefore a significant overlap between the biological effects of S1P, cytokines and growth factors. An early study suggested that the consequences of S1P stimulation of endothelial cells were mediated by activation of the VEGF receptor [75] . This S1P-mediated activation of VEGF was dependent on G␣i protein and Src family kinases. In addition, VEGF can stimulate an increase of S1P receptors, thereby enhancing the potential of S1P to activate VEGF receptors [76] .
Recently, it has been demonstrated that S1P can transactivate the TGF-␤ pathway. TGF-␤ initiates the signal transduction pathway by stimulating the formation of a multimeric receptor complex consisting of two pairs of heterodimers. Each heterodimer consists of two serine-threonine kinases, a type I TGF-␤ receptor (T␤RI) and type II (T␤RII) receptor. The canonical Smad pathway is activated by the binding of TGF-␤ to T␤RII, which then phosphorylates T␤RI. Sauer et al. observed that S1P and TGF-␤ induced phosphorylation of Smad2 and Smad3
, they also showed that S1P mediated activation of Smad3 was GPCR dependent [77] .
The possibility that Smad3 activation was required for S1P induction by keratinocytes was further verified by the observation that neither S1P nor TGF-␤ could induce chemotaxis in keratinocytes derived from Smad3
-/-mice [77] .
Cross talk between S1P and the TGF-␤ signalling pathway has also been observed in renal mesengial cells [78] 
in which T␤RII was required for S1P-mediated activation of Smads and S1P induced TGF-␤ oligomerization. Though the exact mechanism for S1P activation of Smad signalling is not known, this cross-talk is of significance as it impacts on the understanding of various disease processes.
Cross-talk with other GPCR
Leucocytes typically express a range of G-protein coupled chemokine receptors as well as a wide range of other chemotactic and non-chemotactic GPCR. As these receptors may be engaged simultaneously or sequentially by multiple mediators at inflammatory sites, the cellular response is likely to be cross-regulated. Indeed, GPCR are known to be regulated by multiple processes which include down-regulation of both receptor function and cell-surface expression. Receptor desensitization is a process by which receptors become refractory to continued stimulation within minutes of initial agonist exposure. At the point of exit from lymphoid tissue, resting T cells receive signals through both CCR7 and S1PR1. It is suggested that these signals are integrated inside the cells and that the result determines whether they exit or remain inside the tissue. This hypothesis is supported by a number of experiments examining lymphocyte egress in vivo. After FTY720 treatment to down-modulate surface S1PR1, CCR7-deficient T cells egress more efficiently than wild-type T cells. Treatment with pertussin toxin to inactivate
G␣i-dependent signalling of CCR7 restores egress of S1PR1-deficient T cells [79] . It seems that T cells at the boundaries of the cortical sinusoids are desensitized to the CCR7-mediated retention signal by S1P, thus permitting the cells to leave.
Recent evidence has shown that S1P can modulate T-cell chemotaxis in response to certain chemokines. Our group has shown that 1 hr pre-treatment with the S1PR1-specific agonist SEW2871 potently reduced the chemotactic response of resting T cells to CXCL12 (Fig. 5) .
Others have shown that pre-treatment of CD4 ϩ T cells with 10-100 nM S1P resulted in increased chemotaxis of CD4 ϩ T cells towards CCL5 and CCL21, whereas pre-treatment with 300 nM to 3 M S1P strongly suppressed migration towards those chemokines [80] . Strategies to modulate chemotaxis for possible therapeutic benefit are being devised [81] . CXCL12 is an important homeostatic chemokine that regulates the trafficking of lymphocytes and haematopoietic stem cells. S1PR1 overexpression in Jurkat T cells caused a reduction in surface CXCR4 and potent inhibition of ligand-induced chemotaxis and signalling responses [82] . Others have shown that S1P stimulation can support CXCR4-dependent migration, suggesting that the signalling pathways may synergize [83] . One group has identified phosphatidyl inositol 3-kinase as a possible mechanistic link between S1P and enhanced migration towards CXCL12.
There is also evidence for S1P and chemokine receptor crosstalk in neutrophils. S1P can reduce the chemotactic response of neutrophils towards CXCL8 or FMLP; it also antagonizes neutrophil apoptosis and induces pertussis toxin sensitive calcium signals.
Therapies targeting the S1P signalling axis FTY720
Early in vitro experiments using the sphingosine analogue FTY720 did not show any effect until concentrations were increased into the millimolar range (whereupon it induces programmed cell death [84] ), far in excess of the active in vivo concentrations. This has now been explained by the fact that FTY720 is rapidly phosphorylated in vivo by SK2, mostly inside platelets. FTY720-P is structurally similar to S1P and binds all S1P receptors except S1PR2. It binds with similar affinity to S1P at S1PR3, S1PR4 and S1PR5 [30] . Although it is an agonist of S1PR1, it behaves as a functional antagonist. FTY720-P is much more potent than S1P at causing ubiquitination and degradation of S1PR1, even if the concentration of S1P is raised to concentrations sufficient to cause internalization of almost all of the receptor [35, 46, 85] . It is likely that this effect is critical to its ability to render lymphocytes insensitive to egress signals in lymphoid tissue [85] . After treatment of mice with FTY720, lymphocytes can be observed packed next to sinus-lining endothelium but are unable to exit [30] [88, 89] . Some protective immunity is retained, certainly to a much greater extent than following treatment with the calcineurin inhibitors tacrolimus and cyclosporine [90] . FTY720 has been tested in transplantation, but was no better than mycophenolate mofetil in combination with cyclosporine in multiple phase II [91, 92] and phase III [93, 94] [95, 96] . FTY720 shows promise for the treatment of multiple sclerosis, an autoimmune disorder in which autoreactive T cells cross the blood-brain barrier and attack myelin sheaths leading to axonal damage [97] . FTY720 can itself efficiently cross the blood-brain barrier and both FTY720 and FTY720-P accumulate at rather higher concentrations in the central nervous system (CNS) than in the blood [98, 99] . FTY720 has already been through successful phase II trials [100, 101] [102] . The effectiveness of FTY720 in this condition may be due to broader mechanisms of action than inhibition of migration of autoantigen-specific (particularly Th17 cells [103, 104] ) lymphocytes to the CNS [105] . S1P receptors (S1PRs 1, 2, 3 and 5) are expressed at significant levels in the CNS and are believed to play a number of roles in brain cell function, such as controlling astrocyte proliferation and migration, oligodendrocyte differentiation and survival, and neurite outgrowth and neurogenesis [106, 107] .
Monoclonal antibody therapy
A monoclonal antibody of very high specificity and affinity for S1P has been developed. It has proven to be an effective inhibitor of tumour-associated angiogenesis in several murine models [108] . This is likely due to efficient depletion of tumour-associated S1P -which would otherwise drive endothelial cell migration, proliferation and ultimately tumour-supportive neovascularization. This antibody is now undergoing clinical trials for the treatment of cancer and age-related macular degeneration. 
Summary and future directions
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